Related references
Note: Only part of the references are listed.Neoadjuvant checkpoint blockade for cancer immunotherapy
Suzanne L. Topalian et al.
SCIENCE (2020)
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy
Xiaodong Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression
Xiao Albert Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The multiple mechanisms that regulate p53 activity and cell fate
Antonina Hafner et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway
Ning Pu et al.
CANCER LETTERS (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth
Weijia Cai et al.
NATURE COMMUNICATIONS (2019)
p53 modifications: exquisite decorations of the powerful guardian
Yanqing Liu et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2019)
Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
Yunlong Zhao et al.
CELL REPORTS (2018)
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
Shisuo Du et al.
ONCOIMMUNOLOGY (2018)
Cancer Cell-intrinsic PD-1 and implications in Combinatorial immunotherapy
Han Yao et al.
FRONTIERS IN IMMUNOLOGY (2018)
FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells
Xiangbo Meng et al.
NATURE (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Programmed Cell Death-1 (PD-1) Checkpoint Blockade in Combination With a Mammalian Target of Rapamycin Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1
Hui Li et al.
HEPATOLOGY (2017)
Putting p53 in Context
Edward R. Kastenhuber et al.
CELL (2017)
Genetic and Epigenetic Regulation of PD-1 Expression
Alexander P. R. Bally et al.
JOURNAL OF IMMUNOLOGY (2016)
Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode
Donglai Wang et al.
NATURE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
Kyoung Wan Yoon et al.
SCIENCE (2015)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Unravelling mechanisms of p53-mediated tumour suppression
Kathryn T. Bieging et al.
NATURE REVIEWS CANCER (2014)
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Tongyuan Li et al.
CELL (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Colleen A. Brady et al.
CELL (2011)
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma
Karen M. VanderMolen et al.
JOURNAL OF ANTIBIOTICS (2011)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
Modes of p53 Regulation
Jan-Philipp Kruse et al.
CELL (2009)
Acetylation is indispensable for p53 activation
Yi Tang et al.
CELL (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Acetylation of the p53 DNA-binding domain regulates apoptosis induction
Stephen M. Sykes et al.
MOLECULAR CELL (2006)
Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis
Yi Tang et al.
MOLECULAR CELL (2006)
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Lydie Trautmann et al.
NATURE MEDICINE (2006)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
TIGAR, a p53-inducible regulator of glycolysis and apoptosis
Karim Bensaad et al.
CELL (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases
NA Barlev et al.
MOLECULAR CELL (2001)
Share Paper
